Fig. 2From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancerSurvival analysis of patients with CRC according to PRTN3-expression from The Cancer Genome Atlas database. The patients are divided into two groups according to PRTN3 expression/non-expression. a All patients. b Stage I. c Stage II. d Stage III. e Stage IV. Abbreviations: mCRC, metastatic colorectal cancer; PRTN3, proteinase-3Back to article page